New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Seres Therapeutics, Inc.

Contributing Author

Recent Articles by Seres Therapeutics, Inc.

Mar-12	Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates MCRB GlobeNewswire
Mar-02	Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates MCRB GlobeNewswire
Feb-12	Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases MCRB -41.66% GlobeNewswire
Jan-06	Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy MCRB GlobeNewswire
Nov-24	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference MCRB GlobeNewswire
Nov-05	Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates MCRB -7.64% GlobeNewswire
Oct-30	Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 MCRB -6.57% GlobeNewswire
Oct-29	Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 MCRB GlobeNewswire
Oct-14	Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant MCRB GlobeNewswire
Sep-23	Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway MCRB +6.30% GlobeNewswire
Aug-27	Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference MCRB GlobeNewswire
Aug-06	Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates MCRB GlobeNewswire
Jul-22	Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 MCRB -10.54% GlobeNewswire
Jul-22	Seres Therapeutics Announces Leadership Transition MCRB -10.54% GlobeNewswire
May-27	Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting MCRB -5.74% GlobeNewswire
May-07	Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates MCRB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)